Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
GlaxoSmithKline ( (GB:GSK) ) has provided an announcement.
GSK announced that its 5-in-1 meningococcal vaccine, Penmenvy, has received approval from the US FDA for use in individuals aged 10 to 25 years. This vaccine, which protects against the five serogroups of Neisseria meningitidis, aims to improve vaccination rates among US adolescents and young adults, who are at higher risk for invasive meningococcal disease (IMD). The approval positions GSK to enhance its leadership in the US meningococcal vaccine market, with implications for increasing protection against serogroup B, the leading cause of IMD among young people.
More about GlaxoSmithKline
GSK is a global biopharma company dedicated to uniting science, technology, and talent to address disease through innovative healthcare solutions.
YTD Price Performance: 6.57%
Average Trading Volume: 7,810,588
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £58.57B
Find detailed analytics on GSK stock on TipRanks’ Stock Analysis page.
